Women who take single-dose nevirapine to prevent mother-to-child transmission of HIV may not, after all, be jeopardising their own treatment options. here had been concerns that resistance to nevirapine would develop and limit future treatment options if short-course therapy with the drug was used during pregnancy.
A Zambian study involving 4772 women presented to the Toronto conference found that women who subsequently took potent HIV including nevirapine therapy after receiving single-dose nevirapine had comparable CD4 cell increases at six and twelve to women who had not been exposed to single-dose nevirapine prophylaxis.
? Centre for HIV/AIDS Networking 2002 - 2005. All rights reserved. No reproduction, distribution, dissemination or replication of the contents hereof may be undertaken under any circumstances without the express prior written consent of HIVAN. All users acknowledge that they have read and understood our Terms Of Use. Contact Us by clicking here or reach the Webmaster by clicking here.
Please view this site with the latest versions of Explorer or Netscape
